<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921321</url>
  </required_header>
  <id_info>
    <org_study_id>4193</org_study_id>
    <secondary_id>Internal Bridge Funding</secondary_id>
    <nct_id>NCT02921321</nct_id>
  </id_info>
  <brief_title>Pilot Study of Cardiac MR in Patients With Muscular Dystrophy</brief_title>
  <official_title>Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Muscular Dystrophy can affect the skeletal muscles and also the heart and breathing muscles,
      causing significant morbidity and mortality. As patients are now living longer, treatment of
      muscular dystrophies involves drugs that help improve heart function. However, better types
      of heart imaging studies are needed to understand how these treatments work. Researchers want
      to improve heart imaging to identify earlier indicators of heart dysfunction in muscular
      dystrophy patients and how these are changed by medical treatment. The new imaging indicators
      will also help identify candidates for entry into future clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiomyopathy causes significant morbidity and mortality in multiple forms of muscular
      dystrophy affecting children, including Duchenne muscular dystrophy (DMD), Becker muscular
      dystrophy (BMD) and subtypes of autosomal recessive limb-girdle muscular dystrophy (LGMD2).
      Pharmaceutical treatments for the cardiomyopathy of muscular dystrophy, including
      angiotensin-converting enzyme (ACE) inhibition and beta-adrenergic receptor blockade, afford
      significant benefit and demonstrate cardiac remodeling in clinical studies. Further studies
      are needed to identify and characterize more sensitive indicators of cardiac dysfunction in
      muscular dystrophy subjects to better stratify subjects for entry into clinical protocols.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial characterization of fibrosis in patients with muscular dystrophy using contrast based magnetic resonance imaging</measure>
    <time_frame>At the end of each MRI scan through study completion, up to 5 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the amount of intramyocardial fibrosis using extracellular volume measurements</measure>
    <time_frame>At the end of each MRI scan through study completion, up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification and validation of serum biomarker ST2 (Interleukin 1 receptor-like 1 protein ) in the presence of myocardial fibrosis.</measure>
    <time_frame>At the end of the study, up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure regional myocardial strain and correlate with presence of myocardial fibrosis</measure>
    <time_frame>At the end of each MRI scan through study completion, up to 5 years.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Muscular Dystrophies</condition>
  <condition>Cardiac Fibrosis</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Musculoskeletal Diseases</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      An additional 5cc of blood work will be drawn at the time that the intravascular catheter is
      inserted for contrast agent administration for the cardiac MRI scans. This blood will be used
      to identify serum biomarkers in myocardial fibrosis, and to validate the potential use for
      diagnostic purposes. No genetic testing will be done on these samples. The blood samples will
      be identified with the study ID number only, and will be stored in a secure freezer.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male or females at least 6 years of age with a diagnosis of Duchenne, Becker, or Limb
        Girdle Muscular Dystrophy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Duchenne, Becker, or Limb Girdle Muscular Dystrophy

        Exclusion Criteria:

          -  Day-time users of continuous positive airway pressure (CPAP)

          -  Sip ventilator users

          -  Invasive ventilator dependent

          -  Pregnant minors or adults (when uncertain, participants will undergo urine testing) or
             lactating minors and adults

          -  Females who are nursing and who do not plan to discard breast milk for 24 hours

          -  Decompensated congestive heart failure (unable to lie flat during CMR)

          -  Impaired renal excretory function (calculated Glomerular Filtration Rate less than 30
             milliliters/min)

          -  Contra-indications to Magnetic Resonance Imaging:

          -  Cardiac pacemaker or implantable defibrillator

          -  Cerebral aneurysm clip

          -  Neural stimulator

          -  Metallic ocular foreign body

          -  Any implanted device (i.e. insulin pump, drug infusion device)

          -  Claustrophobia

          -  Metal shrapnel or bullet

          -  Investigator assessment of inability to comply with protocol

          -  Unable/unwilling to lie still throughout the research procedure or who require
             sedation

          -  Persons with cognitive impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Spurney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Spurney, MD</last_name>
    <phone>202-476-2020</phone>
    <email>cspurney@childrensnational.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Hamann, RN</last_name>
    <phone>202-476-2317</phone>
    <email>khamann@childrensnational.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987 Dec 24;51(6):919-28.</citation>
    <PMID>3319190</PMID>
  </reference>
  <reference>
    <citation>Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990 Mar;26(3):271-7.</citation>
    <PMID>2312196</PMID>
  </reference>
  <reference>
    <citation>Corrado G, Lissoni A, Beretta S, Terenghi L, Tadeo G, Foglia-Manzillo G, Tagliagambe LM, Spata M, Santarone M. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol. 2002 Apr 1;89(7):838-41.</citation>
    <PMID>11909570</PMID>
  </reference>
  <reference>
    <citation>Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 Jun 15;320(24):1592-7.</citation>
    <PMID>2657428</PMID>
  </reference>
  <reference>
    <citation>Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol. 1997 May;12(3):329-43. Review.</citation>
    <PMID>9243091</PMID>
  </reference>
  <reference>
    <citation>Deburgrave N, Daoud F, Llense S, Barbot JC, Récan D, Peccate C, Burghes AH, Béroud C, Garcia L, Kaplan JC, Chelly J, Leturcq F. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat. 2007 Feb;28(2):183-95.</citation>
    <PMID>17041906</PMID>
  </reference>
  <reference>
    <citation>Mathews KD, Moore SA. Limb-girdle muscular dystrophy. Curr Neurol Neurosci Rep. 2003 Jan;3(1):78-85. Review.</citation>
    <PMID>12507416</PMID>
  </reference>
  <reference>
    <citation>Lim LE, Campbell KP. The sarcoglycan complex in limb-girdle muscular dystrophy. Curr Opin Neurol. 1998 Oct;11(5):443-52. Review.</citation>
    <PMID>9847993</PMID>
  </reference>
  <reference>
    <citation>Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol. 2008 Nov 1;102(9):1131-5. doi: 10.1016/j.amjcard.2008.06.036. Epub 2008 Aug 27.</citation>
    <PMID>18940278</PMID>
  </reference>
  <reference>
    <citation>Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, Miller DH, Reis G, Alderman MH, Laragh JH. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984 Dec;4(6):1222-30.</citation>
    <PMID>6238987</PMID>
  </reference>
  <reference>
    <citation>Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, Wong ND, Smith VE, Gottdiener J. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol. 2001 May 1;87(9):1051-7.</citation>
    <PMID>11348601</PMID>
  </reference>
  <reference>
    <citation>Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998 Nov;32(5):1454-9.</citation>
    <PMID>9809962</PMID>
  </reference>
  <reference>
    <citation>Lavie CJ, Milani RV, Ventura HO, Messerli FH. Left ventricular geometry and mortality in patients &gt;70 years of age with normal ejection fraction. Am J Cardiol. 2006 Nov 15;98(10):1396-9. Epub 2006 Oct 2.</citation>
    <PMID>17134637</PMID>
  </reference>
  <reference>
    <citation>Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P, Gorini M, Maggioni AP; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001 Dec;38(7):1829-35.</citation>
    <PMID>11738281</PMID>
  </reference>
  <reference>
    <citation>Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, Folsom AR. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008 Dec 16;52(25):2148-55. doi: 10.1016/j.jacc.2008.09.014.</citation>
    <PMID>19095132</PMID>
  </reference>
  <reference>
    <citation>Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med. 1970 Jun;72(6):813-22.</citation>
    <PMID>4247338</PMID>
  </reference>
  <reference>
    <citation>Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med. 1989 Jan 15;110(2):101-7.</citation>
    <PMID>2521199</PMID>
  </reference>
  <reference>
    <citation>Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990 May 31;322(22):1561-6.</citation>
    <PMID>2139921</PMID>
  </reference>
  <reference>
    <citation>Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004 Sep 14;110(11):1456-62. Epub 2004 Aug 23.</citation>
    <PMID>15326072</PMID>
  </reference>
  <reference>
    <citation>Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004 Nov 17;292(19):2350-6.</citation>
    <PMID>15547162</PMID>
  </reference>
  <reference>
    <citation>Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002 Sep 25;288(12):1491-8.</citation>
    <PMID>12243636</PMID>
  </reference>
  <reference>
    <citation>Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004 Nov 17;292(19):2343-9.</citation>
    <PMID>15547161</PMID>
  </reference>
  <reference>
    <citation>Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens. 1995 Mar;8(3):221-8.</citation>
    <PMID>7794570</PMID>
  </reference>
  <reference>
    <citation>Caiani EG, Corsi C, Sugeng L, MacEneaney P, Weinert L, Mor-Avi V, Lang RM. Improved quantification of left ventricular mass based on endocardial and epicardial surface detection with real time three dimensional echocardiography. Heart. 2006 Feb;92(2):213-9. Epub 2005 May 12.</citation>
    <PMID>15890763</PMID>
  </reference>
  <reference>
    <citation>Hees PS, Fleg JL, Lakatta EG, Shapiro EP. Left ventricular remodeling with age in normal men versus women: novel insights using three-dimensional magnetic resonance imaging. Am J Cardiol. 2002 Dec 1;90(11):1231-6.</citation>
    <PMID>12450604</PMID>
  </reference>
  <reference>
    <citation>Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009 Feb 3;119(4):530-7. doi: 10.1161/CIRCULATIONAHA.108.826214. Epub 2009 Jan 19.</citation>
    <PMID>19153265</PMID>
  </reference>
  <reference>
    <citation>de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J. 2009 Apr;157(4):746-53.e2. doi: 10.1016/j.ahj.2008.12.017. Epub 2009 Feb 20.</citation>
    <PMID>19332205</PMID>
  </reference>
  <reference>
    <citation>Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology. 2001 Mar;218(3):703-10.</citation>
    <PMID>11230643</PMID>
  </reference>
  <reference>
    <citation>Wu YL, Ye Q, Sato K, Foley LM, Hitchens TK, Ho C. Noninvasive evaluation of cardiac allograft rejection by cellular and functional cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009 Jun;2(6):731-41. doi: 10.1016/j.jcmg.2009.01.013.</citation>
    <PMID>19520344</PMID>
  </reference>
  <reference>
    <citation>Harris PA, Lorenz CH, Holburn GE, Overholser KA. Regional measurement of the Gd-DTPA tissue partition coefficient in canine myocardium. Magn Reson Med. 1997 Oct;38(4):541-5.</citation>
    <PMID>9324319</PMID>
  </reference>
  <reference>
    <citation>Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008 Sep;295(3):H1234-H1242. doi: 10.1152/ajpheart.00429.2008. Epub 2008 Jul 25.</citation>
    <PMID>18660445</PMID>
  </reference>
  <reference>
    <citation>Pack NA, Dibella EV, Wilson BD, McGann CJ. Quantitative myocardial distribution volume from dynamic contrast-enhanced MRI. Magn Reson Imaging. 2008 May;26(4):532-42. Epub 2008 Feb 20.</citation>
    <PMID>18068931</PMID>
  </reference>
  <reference>
    <citation>Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991 Jun;83(6):1849-65. Review.</citation>
    <PMID>1828192</PMID>
  </reference>
  <reference>
    <citation>van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990 Sep;82(3):848-55.</citation>
    <PMID>2394006</PMID>
  </reference>
  <reference>
    <citation>Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998 Jul;16(7):1031-41.</citation>
    <PMID>9794745</PMID>
  </reference>
  <reference>
    <citation>McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens. 1990 Oct;3(10):735-40.</citation>
    <PMID>2145865</PMID>
  </reference>
  <reference>
    <citation>Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Sonnenblick EH, Olivetti G, Anversa P. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol. 1995 Jan;27(1):291-305.</citation>
    <PMID>7760353</PMID>
  </reference>
  <reference>
    <citation>Anderson KP, Walker R, Urie P, Ershler PR, Lux RL, Karwandee SV. Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1993 Jul;92(1):122-40.</citation>
    <PMID>8325977</PMID>
  </reference>
  <reference>
    <citation>de Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de Jonge N, Lahpor JR. Fractionated electrograms in dilated cardiomyopathy: origin and relation to abnormal conduction. J Am Coll Cardiol. 1996 Apr;27(5):1071-8.</citation>
    <PMID>8609323</PMID>
  </reference>
  <reference>
    <citation>Kawara T, Derksen R, de Groot JR, Coronel R, Tasseron S, Linnenbank AC, Hauer RN, Kirkels H, Janse MJ, de Bakker JM. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation. 2001 Dec 18;104(25):3069-75.</citation>
    <PMID>11748102</PMID>
  </reference>
  <reference>
    <citation>Castillo E, Osman NF, Rosen BD, El-Shehaby I, Pan L, Jerosch-Herold M, Lai S, Bluemke DA, Lima JA. Quantitative assessment of regional myocardial function with MR-tagging in a multi-center study: interobserver and intraobserver agreement of fast strain analysis with Harmonic Phase (HARP) MRI. J Cardiovasc Magn Reson. 2005;7(5):783-91.</citation>
    <PMID>16358393</PMID>
  </reference>
  <reference>
    <citation>Fernandes VR, Polak JF, Cheng S, Rosen BD, Carvalho B, Nasir K, McClelland R, Hundley G, Pearson G, O'Leary DH, Bluemke DA, Lima JA. Arterial stiffness is associated with regional ventricular systolic and diastolic dysfunction: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):194-201. Epub 2007 Oct 25.</citation>
    <PMID>17962621</PMID>
  </reference>
  <reference>
    <citation>Osman NF, Prince JL. Visualizing myocardial function using HARP MRI. Phys Med Biol. 2000 Jun;45(6):1665-82.</citation>
    <PMID>10870717</PMID>
  </reference>
  <reference>
    <citation>Rosen BD, Saad MF, Shea S, Nasir K, Edvardsen T, Burke G, Jerosch-Herold M, Arnett DK, Lai S, Bluemke DA, Lima JA. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2006 Mar 21;47(6):1150-8. Epub 2006 Feb 23.</citation>
    <PMID>16545644</PMID>
  </reference>
  <reference>
    <citation>de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation. 1996 Jan 15;93(2):259-65.</citation>
    <PMID>8548897</PMID>
  </reference>
  <reference>
    <citation>Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med. 1991 Dec;22(2):222-8; discussion 229-32. Review.</citation>
    <PMID>1812350</PMID>
  </reference>
  <reference>
    <citation>Viollet L, Gailey S, Thornton DJ, Friedman NR, Flanigan KM, Mahan JD, Mendell JR. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve. 2009 Sep;40(3):438-42. doi: 10.1002/mus.21420.</citation>
    <PMID>19623638</PMID>
  </reference>
  <reference>
    <citation>Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochmüller H, Ginjaar HB, Aartsma-Rus AM, van Ommen GJ, den Dunnen JT, 't Hoen PA. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord. 2011 Aug;21(8):569-78. doi: 10.1016/j.nmd.2011.05.011. Epub 2011 Jul 2.</citation>
    <PMID>21724396</PMID>
  </reference>
  <reference>
    <citation>Hollingsworth KG, Garrood P, Eagle M, Bushby K, Straub V. Magnetic resonance imaging in Duchenne muscular dystrophy: longitudinal assessment of natural history over 18 months. Muscle Nerve. 2013 Oct;48(4):586-8. doi: 10.1002/mus.23879. Epub 2013 Aug 30.</citation>
    <PMID>23620230</PMID>
  </reference>
  <reference>
    <citation>Cao Y, Huang DQ, Shih G, Prince MR. Signal Change in the Dentate Nucleus on T1-Weighted MR Images After Multiple Administrations of Gadopentetate Dimeglumine Versus Gadobutrol. AJR Am J Roentgenol. 2016 Feb;206(2):414-9. doi: 10.2214/AJR.15.15327. Epub 2015 Dec 23.</citation>
    <PMID>26700156</PMID>
  </reference>
  <reference>
    <citation>Jost G, Lenhard DC, Sieber MA, Lohrke J, Frenzel T, Pietsch H. Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents: Comparison of Linear and Macrocyclic Agents. Invest Radiol. 2016 Feb;51(2):83-9. doi: 10.1097/RLI.0000000000000242.</citation>
    <PMID>26606548</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Research Institute</investigator_affiliation>
    <investigator_full_name>Christopher Spurney</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <keyword>Cardiac</keyword>
  <keyword>Late gadolinium enhancement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

